A trial of prophylactic thiotepa or mitomycin C intravesical therapy in patients with recurrent or multiple superficial bladder cancers

R. C. Flanigan, M. F. Ellison, K. M. Butler, L. G. Gomella, J. W. McRoberts

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

There were 40 consecutive patients with recurrent or multiple superficial stage Ta or T1 transitional cell cancer assigned randomly to receive prophylactic thiotepa or mitomycin C intravesical chemotherapy. Patients received 8 weekly instillations followed by 22 monthly treatments of either 60 mg. thiotepa or 40 mg. mitomycin C. Of 25 patients randomized to receive mitomycin C 4 had recurrence in a total of 337 patient-months (1.19 per 100 patient-months), while disease recurred in 1 of 15 patients randomized to receive thiotepa who were followed for a total of 220 patient-months (0.45 per 100 patient-months). No significant difference in recurrence rate was noted for either drug group (p equals 0.18). Toxicity requiring cessation of therapy was observed in 7 patients (28 per cent) on mitomycin C and none on thiotepa.

Original languageEnglish
Pages (from-to)35-37
Number of pages3
JournalJournal of Urology
Volume136
Issue number1
DOIs
StatePublished - 1986

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'A trial of prophylactic thiotepa or mitomycin C intravesical therapy in patients with recurrent or multiple superficial bladder cancers'. Together they form a unique fingerprint.

Cite this